OAC
GALT icon

OMERS Administration Corp’s Galectin Therapeutics GALT Stock Holding History

OMERS Administration Corp’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,100
Closed -$67.2K – 1005
2026
Q1 		$67.2K Sell
24,100
-39,100
-62% -$119K ﹤0.01% 1049
2025
Q4 		$263K Buy
+63,200
New +$333K ﹤0.01% 844

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

OMERS Administration Corp's GALT Position: Q2 2026 in Review

OMERS Administration Corp sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 24,100 shares — an estimated $67.2K sold.

OMERS Administration Corp first reported a position in GALT in Q4 2025 and held it in 2 quarters. The position peaked at $263K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • OMERS Administration Corp reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 24,100 Galectin Therapeutics shares in Q2 2026, an estimated $67.2K.
  • OMERS Administration Corp first reported a position in Galectin Therapeutics in Q4 2025 and held it in 2 quarters.
  • OMERS Administration Corp's Galectin Therapeutics position peaked at $263K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.